Skip to Main Content

Ketamine for Adolescent Suicidality

Conditions

Mental Health & Behavioral Research

Phase II

What is the purpose of this trial?

The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking compared to an active placebo (midazolam) in adolescents who have treatment resistant depression and a recent history of a suicide event (defined as a suicide attempt, emergency room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in the past 120 days).

The primary objective of this study is to determine whether ketamine reduces suicidal ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control, midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.

  • Trial with
    National Institutes of Health (NIH)
  • Start Date
    01/21/2022
  • End Date
    12/31/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/28/2022
  • Study HIC
    #2000029003